Berenson Cancer Center Reports Record 13-Year Survival for Multiple Myeloma Patients Without Standard Transplant Therapy
核心洞察
Berenson Cancer Center (搜索) achieved an unprecedented average survival of nearly 13 years in 175 consecutive multiple myeloma (搜索) patients, representing the longest reported survival in any unselected patient group to date.
The remarkable outcomes were achieved without using stem cell transplants as first-line therapy, with only one patient receiving transplant after initial treatment and no patients receiving CAR-T cell therapy (搜索) or bispecific antibodies (搜索).
The success was attributed to highly individualized care including more treatment options than used anywhere else globally, 24-hour physician access, and frequent monitoring allowing rapid treatment adjustments.
Berenson Cancer Center (搜索) has reported the longest survival outcomes ever documented for multiple myeloma (搜索) patients, with an average survival of nearly 13 years among 175 consecutive and unselected patients treated between 2006 and 2024. The findings, published in Haematologica by the Institute for Myeloma & Bone Cancer Research (搜索), represent a significant departure from conventional treatment approaches and challenge current therapeutic paradigms.
Unprecedented Outcomes Without Standard Transplant Protocols
The study's most striking finding is that these record survival rates were achieved without following standard treatment protocols used at other myeloma centers. Unlike conventional approaches that consider stem cell transplant (搜索) as a standard component of initial therapy, none of the patients in this study underwent transplantation as their first treatment, with only one patient receiving it subsequently. Additionally, no patients were treated with CAR-T cell therapy (搜索) or bispecific antibodies (搜索).
"The unprecedented outcomes in this study were achieved without use of any of these treatments," the study authors noted, highlighting the effectiveness of their alternative approach.
Individualized Care Model Drives Success
According to Dr. James R. Berenson, the study's senior author and President & Medical Director of Berenson Cancer Center (搜索), the exceptional results stem from a comprehensive individualized care model. "The highly individualized care multiple myeloma (搜索) patients receive includes more treatment options than used anywhere in the world," Dr. Berenson explained.
Key components of their approach include:
- 24-hour direct access to treating physicians
- More frequent regular monitoring of disease status
- Rapid treatment modifications when therapies are ineffective or causing adverse effects
- Extensive treatment options exceeding those available elsewhere globally
Dr. Berenson, who brings over 40 years of hands-on experience treating multiple myeloma (搜索) patients, believes this extensive clinical experience has enabled the identification of more effective treatments and expertise in optimizing therapeutic outcomes.
Significant Clinical Impact for Growing Patient Population
The findings have particular relevance given the substantial patient population affected by multiple myeloma (搜索). Nearly 40,000 Americans are expected to receive a multiple myeloma diagnosis in 2025, with approximately 200,000 individuals currently living with this bone marrow-based cancer.
The study's comprehensive nature, including all consecutive patients with multiple myeloma (搜索) who initiated treatment at the specialized clinic over an 18-year period, provides robust evidence for the effectiveness of this alternative treatment paradigm.
Implications for Current Treatment Standards
These results raise important questions about current treatment protocols that routinely incorporate stem cell transplantation as first-line therapy. The Berenson Cancer Center (搜索)'s approach demonstrates that exceptional outcomes may be achievable through intensive monitoring, individualized treatment selection, and immediate physician accessibility, potentially offering patients an alternative to more invasive procedures.
The study's methodology of including all consecutive and unselected patients strengthens the validity of the findings, as it eliminates selection bias that might favor certain patient populations in other studies. This comprehensive approach provides a more accurate representation of real-world treatment outcomes across diverse patient presentations and disease characteristics.